Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 14/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.52 |
| ▸ | HRH2 | P25021 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 3/20 | 0.52 |
| ▸ | HRH1 | P35367 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27041869 | 0.93 | TMEM97 (0.67) | TMEM97SIGMAR1ADRA2AADRA2BHRH2 | |
| SCHEMBL325572 | 0.93 | TMEM97 (0.67) | TMEM97SIGMAR1ADRA2AADRA2BHRH2 | |
| SCHEMBL15056469 | 0.86 | NPC1 (0.67) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL1506610 | 0.84 | TMEM97 (0.63) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL1294235 | 0.82 | NR1H2 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL5215787 | 0.81 | NPC1 (0.72) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL1945831 | 0.81 | TMEM97 (0.56) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL6295401 | 0.80 | NPC1 (0.53) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL324228 | 0.80 | TMEM97 (0.67) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL30515329 | 0.80 | TMEM97 (0.70) | TMEM97SIGMAR1ADRA2AADRA2BHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | LECTUS THERAPEUTICS LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | LECTUS THERAPEUTICS LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | LECTUS THERAPEUTICS LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-2069309-A1 | ION CHANNEL MODULATORS&USES THEREOF | Lectus Therapeutics Limited (GB) | 2009-06-17 | — | — | EP | disclosed |
| EP-2066317-A2 | USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES | Lectus Therapeutics Limited (GB) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008038053-A1 | ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008038053-A1 | ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008038051-A2 | USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES | LECTUS THERAPEUTICS LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008038051-A2 | USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES | LECTUS THERAPEUTICS LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | KCNH3, KCNN3, KCNH2 | TMEM97 516/4885SIGMAR1 233/4885MEN1 3637/4885 |
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | HCAR2, HCAR1, SCN7A | TMEM97 851/4885SIGMAR1 233/4885MEN1 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.